Результаты поиска

Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Classical Hodgkin's lymphoma (cHL) is a B-cell malignancy comprised of pathologic Reed Sternberg cells with a surrounding immune-tolerant inflammatory milieu. RS cells evade immune recognition in part through programmed death ligand 1 (PD-L1) overexpression, which is genetically programmed through copy number alterations, polysomy, and amplification of the 9p24.1 locus encoding PD-L1. By engaging with PD-1+ T-cells, PD-L1 delivers a potent immune suppressive signal promoting immunologic escape of the tumor cell. Enhancing antitumor immune response by targeting PD-1 with the monoclonal antibody

Совпадение в полном тексте источника
… 2010 28 19 3167 3175 20516446 10.1200/JCO.2009.26.7609 PMC4834717 68 Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 26 2443 2454 22658127 10.1056/NEJMoa1200690 PMC3544539 69 Borghaei H Paz-Ares L Horn L Nivolumab versus docetaxel … in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015 373 17 1627 1639 26412456 10.1056/NEJMoa1507643 PMC5705936 70 Brahmer J Reckamp KL Baas P Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 2015 373 2 123 135 26028407 10.1056/NEJMoa1504627 …

Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

BackgroundConsensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal o

Совпадение в полном тексте источника
… staging of non-small-cell lung cancer: aclinical practice guideline [42] | 2011 | | 75 | 83 | Management of a suspicious adnexal mass: a clinicalpractice guideline [43] | 2012 | | 80 | 63 | Lenalidomide in multiple myeloma – a practice guideline [44] | 2013 | | 75 | 83 | Chemotherapy (gemcitabine, docetaxel … Gupta AA, Yao X, Verma S, Mackay H, Hopkins L (2013) Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline. Curr Oncol 20: e448–454. 46. …

Recent advances in anti-angiogenic therapy of cancer.

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.

Совпадение в полном тексте источника
… In a Phase I trial of metronomic dosing of docetaxel and thalidomide, of the 26 patients with advanced tumors enrolled, prolonged freedom from disease progression was observed in 44.4% of the evaluable patients [ 135 ]. … metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients Oncol Rep 2006 16 133 40 16786136 10.3892/or.16.1.133 135 Sanborn SL Cooney MM Dowlati A Brell JM Krishnamurthi S Gibbons J Bokar JA Nock C Ness A Remick SC Phase i trial of docetaxel …

Antibodies to watch in 2023.

In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevim

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.

Lymph nodes (LNs) are important hubs for metastatic cell arrest and growth, immune modulation, and secondary dissemination to distant sites through a series of mechanisms, and it has been proved that lymph node metastasis (LNM) is an essential prognostic indicator in many different types of cancer. Therefore, it is important for oncologists to understand the mechanisms of tumor cells to metastasize to LNs, as well as how LNM affects the prognosis and therapy of patients with cancer in order to provide patients with accurate disease assessment and effective treatment strategies. In recent years

Совпадение в полном тексте источника
… Based on JCOG 0405, the JCOG1002 trial added docetaxel to the S-1 plus cisplatin with the goal of attaining better response and survival rates, 182 although this regimen was ultimately associated with a response rate below that from the JCOG 0405 study, albeit with a 62% 3-year survival rate. …

The challenge of chemotherapy-related cognitive impairment: assessing and managing cognitive decline after cancer treatment.

Chemotherapy-related cognitive impairment (CRCI) refers to a decline in cognitive function in patients during and after cancer treatment and is mainly associated with the use of cytotoxic chemotherapy (CT). As CT is still an essential component in the treatment of many cancers and taking into account the fact that cancer survival rates are increasing, CRCI may negatively impact the quality of life and working capacity of a growing number of individuals, especially those treated with curative intent in conditions such as breast cancer. There is still a need to address several issues related to

Совпадение в полном тексте источника
… Breast cancer*, Endometrial cancer**, Ewing’s sarcoma*, Gastric cancer*, Hepatic carcinoma**, Hodgkin's Lymphoma*, Kaposi’s sarcoma***, Multiple myeloma*, Non-Hodgkin's Lymphoma*, Osteosarcoma*, Soft tissue sarcoma**, Thyroid carcinoma***, Thymoma*, Wilm’s tumour* Taxanes (Cabazitaxel – Jevtana ® ) (Docetaxel … – Docefrez ® , Taxotere ® ) (Paclitaxel – Taxol ®, Onxol ® ) | Clinical studies: attention, concentration, executive functions Animal models: spatial memory | Decreased hippocampal neurogenesis Changes in neuronal morphology | Cabazitaxel Prostate cancer*** | Docetaxel Breast cancer**, Ewing's sarcoma …

Qualitative exploration of the perceptions of exercise in patients with cancer initiated during chemotherapy: a meta-synthesis.

ObjectiveTo synthesise qualitative literature on (1) the perceptions of patients with cancer of participating in an exercise intervention while undergoing chemotherapy and (2) to inform and guide professionals in oncology and haematology practice.DesignA qualitative meta-synthesis based on Noblit and Hare's seven-step meta-ethnography.Data sourcesSix electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, EMBASE, PubMed, SCI-Expanded-SSCI and Scopus (final search June 2022) were used to identify qualitative literature containing individual or focus group intervi

Совпадение в полном тексте источника
… or waitlist control group | Interpretative phenomenological analysis (IPA) | Denmark | 2017 Andersen et al 55 | To explore the perceptions and management of muscle and joint pain experienced by participants in the Body & Cancer programme who received adjuvant epirubicin, cyclophosphamide followed by docetaxel … Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, Epirubicin and fluorouracil compared with Docetaxel + Epirubicin and cyclophosphamide . …

Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list.

PurposeTo assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China's 2020 National Reimbursement Drug List (NRDL).MethodsA comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in China's 2020 NRDL using the PubMed/MEDLINE, Embase, Web of Science, CNKI, SinoMed, and WanFang Database up to March 31, 2021. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist scored the reporting quality between 0 and 100. A linear regression analysis was employed to exami

Совпадение в полном тексте источника
… Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in third-line treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China. Clin Ther. 2020;42(11):2159–70.e2156. doi: 10.1016/j.clinthera.2020.08.018. 40. Wen F, Zheng H, Zhang P, Liao W, Zhou K, Li Q. … Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china. Cost Eff Resour Alloc. 2021;19(1):11. doi: 10.1186/s12962-021-00264-w. 54. …

Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).

Cancer patients have an increased risk of developing venous thromboembolic events. Anticoagulation management includes prophylactic or therapeutic doses of low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs). However, the management of thrombosis in patients with cancer is complex due to various individual and disease-related factors, including drug-drug interactions (DDIs). Furthermore, DDIs may impact both, cancer and venous thrombosis, treatment effectiveness and safety; their relevance is highlighted by the advances in cancer therapeutics. Given that these new oncol

Совпадение в полном тексте источника
… inducer and substrate No No 20-70% Lung, Melanoma Dabrafenib Moderate inducer/transient inhibitor and substrate Substrate Inhibitor and substrate 99.7% Melanoma, Sarcomas Dacarbazine No No No 5% Biliary, Bladder, Breast, CUP, Head&Neck, Pancreas, Oesophagus, Gastric, Lung, Ovarian, Prostate, Sarcomas Docetaxel … No | 20-70% Lung, Melanoma | Dabrafenib | Moderate inducer/transient inhibitor and substrate | Substrate | Inhibitor and substrate | 99.7% Melanoma, Sarcomas | Dacarbazine | No | No | No | 5% Biliary, Bladder, Breast, CUP, Head&Neck, Pancreas, Oesophagus, Gastric, Lung, Ovarian, Prostate, Sarcomas | Docetaxel …

Nanoparticle-Based Drug Delivery System: A Patient-Friendly Chemotherapy for Oncology.

Chemotherapy is widely used to treat cancer. The toxic effect of conventional chemotherapeutic drugs on healthy cells leads to serious toxic and side effects of conventional chemotherapy. The application of nanotechnology in tumor chemotherapy can increase the specificity of anticancer agents, increase the killing effect of tumors, and reduce toxic and side effects. Currently, a variety of formulations based on nanoparticles (NPs) for delivering chemotherapeutic drugs have been put into clinical use, and several others are in the stage of development or clinical trials. In this review, after b

Совпадение в полном тексте источника
… Product name | Encapsulated drugs | Type of liposomes | Indications | Status | Ref Alocrest | Vinorelbine | Optisomes | NSCLC and breast cancers, non-Hodgkin lymphoma, Hodgkin disease | Phase I | 60 ATI-1123 | Docetaxel | Protein-stabilized liposomes | NSCLC, gastric, pancreatic cancer, and soft tissue … Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors . Cancer Chemother Pharmacol . 2014 ; 74 ( 6 ): 1241 – 1250 . 25304209 10.1007/s00280-014-2602-x 62 Hamaguchi T Matsumura Y Nakanishi Y , et al. …

Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.

Androgen-deprivation therapy (ADT) is a systemic therapy administered for the management of advanced prostate cancer (PCa). Although ADT may improve survival, long-term use reduces bone mass density (BMD), posing an increased risk of fracture. Considering the long natural history of PCa, it is essential to preserve bone health and quality-of-life in patients on long-term ADT. As an alternative to pharmacological interventions targeted at preserving BMD, current evidence recommends lifestyle modifications, including individualized exercise and nutritional interventions. Exercise interventions i

Совпадение в полном тексте источника
… Docetaxel chemotherapy and androgen receptor axis-targeted agents, including abiraterone or enzalutamide, have shown clinical efficacy in patients with castration-resistant PCa (CRPC) [ 4 ]. … Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New Engl. J. Med. 2004;351:1502–1512. doi: 10.1056/NEJMoa040720. 9. Saad F., Ivanescu C., Phung D., Loriot Y., Abhyankar S., Beer T.M., Tombal B., Holmstrom S. …

Molecular therapeutic strategies targeting pancreatic cancer induced cachexia.

Pancreatic cancer (PC) induced cachexia is a complex metabolic syndrome associated with significantly increased morbidity and mortality and reduced quality of life. The pathophysiology of cachexia is complex and poorly understood. Many molecular signaling pathways are involved in PC and cachexia. Though our understanding of cancer cachexia is growing, therapeutic options remain limited. Thus, further discovery and investigation of the molecular signaling pathways involved in the pathophysiology of cachexia can be applied to development of targeted therapies. This review focuses on three main p

Совпадение в полном тексте источника
… Combining etanercept with docetaxel in patients with advanced cancer has demonstrated improvement in chemotolerance and reduced fatigue[ 65 , 66 ]. Conversely, combination etanercept and gemcitabine therapy did not provide obvious benefit to PC patients in clinical trials[ 51 ]. … Phase I and Biological Study of Etanercept and Weekly Docetaxel in Patients With Advanced Solid Tumors. [accessed 2017 Dec 6] In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. …

Dissecting the role of bone marrow stromal cells on bone metastases.

Tumor-induced bone disease is a dynamic process that involves interactions with many cell types. Once metastatic cancer cells reach the bone, they are in contact with many different cell types that are present in the cell-rich bone marrow. These cells include the immune cells, myeloid cells, fibroblasts, osteoblasts, osteoclasts, and mesenchymal stem cells. Each of these cell populations can influence the behavior or gene expression of both the tumor cells and the bone microenvironment. Additionally, the tumor itself can alter the behavior of these bone marrow cells which further alters both t

Совпадение в полном тексте источника
… However, recent phase III clinical trial results showed that addition of dasatinib (a Src family kinase inhibitor) to docetaxel did not significantly improve overall survival of castration-resistant prostate cancer patients [ 36 ]. … Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet Oncology. 2013;14(13):1307–1316. doi: 10.1016/S1470-2045(13)70479-0. 37. Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. …

Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.

In recent years, nano-drug delivery systems (Nano-DDS) that target the tumor microenvironment (TME) to overcome multidrug resistance (MDR) have become a research hotspot in the field of cancer therapy. By precisely targeting the TME and regulating its unique pathological features, such as hypoxia, weakly acidic pH, and abnormally expressed proteins, etc., these Nano-DDS enable effective delivery of therapeutic agents and reversal of MDR. This scientific research community is increasing its investment in the development of diversified systems and exploring their anti-drug resistance potential.

Совпадение в полном тексте источника
… Moreover, BIND-014, which consists of PSMA-targeting docetaxelamine granules, is a docetaxel therapy specifically designed to target prostate-specific membrane antigen (PSMA). This targeting mechanism enhances the delivery of the drug to tumor cells. … By loading docetaxel into PSMA-targeted nanoparticles, BIND-014 increased drug concentration within resistant tumor cells, showing promise in overcoming MDR 176 . …

Selenium Compounds as Novel Potential Anticancer Agents.

The high number of new cancer incidences and the associated mortality continue to be alarming, leading to the search for new therapies that would be more effective and less burdensome for patients. As there is evidence that Se compounds can have chemopreventive activity, studies have begun to establish whether these compounds can also affect already existing cancers. This review aims to discuss the different classes of Se-containing compounds, both organic and inorganic, natural and synthetic, and the mechanisms and molecular targets of their anticancer activity. The chemical classes discussed

Совпадение в полном тексте источника
… Furthermore, it was reported that apart from synergistic enhancement, SeL also reduced the side effects (e.g., toxicity) of commonly used cytostatic drugs, among other (a.o.) 5-fluorouracil (5-FU) or docetaxel [ 6 ]. … ClinicalTrials.gov Phase I Sodium Selenite in Combination with Docetaxel in Castration-resistant Prostate Cancer. [(accessed on 7 January 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT01155791 . 42. …

Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare.

Vitamin D has received a lot of attention recently as a result of a meteoric rise in the number of publications showing that vitamin D plays a crucial role in a plethora of physiological functions and associating vitamin D deficiency with many acute and chronic illnesses including disorders of calcium metabolism, autoimmune diseases, some cancers, type 2 diabetes mellitus, infectious diseases and cardiovascular disease. The recent data on vitamin D from experimental, ecological, case-control, retrospective and prospective observational studies, as well as smaller intervention studies, are sign

Совпадение в полном тексте источника
… There have been case reports of mucocutaneous side effects (e.g., stomatitis) and taste disorders occurring in cancer patients under polychemotherapy with TCH (T: docetaxel, C: carboplatin, H: trastuzumab) or FOLFOX6, which could be treated successfully with supplementation of vitamin D 3 . 126 Also, … Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol. 2010;21:185–6. doi: 10.1093/annonc/mdp497. 125. Fink M. …

Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature.

UNLABELLED: We present the case of a 53-year-old woman treated with analgesic radiotherapy for a multiple myeloma bone lesion of the forearm. After a first fraction of 5 Gray (Gy), she presented with an acute respiratory syndrome with fever a few hours after the treatment. The same symptoms occurred after the second fraction 3 days later. The patient recovered quickly thanks to intravenous hydration and suspension of the radiotherapy. Biological tests revealed a tumor lysis syndrome. We concluded that the clinical symptoms could be defined as cytokine release syndrome. This is the second time

Совпадение в полном тексте источника
… VincristineTenoposide | [28] Neuroblastoma | 3 months | Hepatic5 Gy/5F | Dose not reported | Resolved | 1994 | No | [28] Neuroblastoma | 2 days | Hepatic5 Gy/5F | Dose not reported | Resolved | 1994 | VincristineTenoposide | [28] Prostate cancer | 60y | Bone30 Gy/10F | 6th day of RT | Death | 2012 | Docetaxel …

Keyword Index for Volume 95

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 1582 dietary factor 1586 digestive cancer 944 dihydropyrimidine dehydrogenase 607 discrete choice experiment 1448 distance 944 distant metastases 710 DNA damage 520, 1514 DNA fragmentation factor 1696 DNA methylation 541 DNA ploidy pattern 817 DNA repair gene 561 DNA topoisomerase 1 906 docetaxel …

Liposomes for the Treatment of Brain Cancer-A Review.

Due to their biocompatibility, non-toxicity, and surface-conjugation capabilities, liposomes are effective nanocarriers that can encapsulate chemotherapeutic drugs and facilitate targeted delivery across the blood-brain barrier (BBB). Additionally, strategies have been explored to synthesize liposomes that respond to internal and/or external stimuli to release their payload controllably. Although research into liposomes for brain cancer treatment is still in its infancy, these systems have great potential to fundamentally change the drug delivery landscape. This review paper attempts to consol

Совпадение в полном тексте источника
… In another study, Muthu et al. [ 131 ] developed liposomes coated with d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), a PEGylated vitamin E, and loaded them with docetaxel (DTX) as a model drug for the improved treatment of brain tumors. … In a similar investigation, theranostic liposomes decorated with RGD-TPGS and co-loaded with docetaxel and QDs were tested in vivo on Charles Foster rats [ 132 ]. These liposomes had a mean particle size of 175.6 ± 3.2 nm. …

Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.

CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein 9) shows the opportunity to treat a diverse array of untreated various genetic and complicated disorders. Therapeutic genome editing processes that target disease-causing genes or mutant genes have been greatly accelerated in recent years as a consequence of improvements in sequence-specific nuclease technology. However, the therapeutic promise of genome editing has yet to be explored entirely, many challenges persist that increase the risk of further mutations. Here, we highlighted the main challenges fa

Совпадение в полном тексте источника
… In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer. Life Sci Alliance. 2020;3(12):e202000770. 10.26508/lsa.202000770. 68. Jiang FN, Liang YX, Wei W, Zou CY, Chen GX, Wan YP, et al. … Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35. doi: 10.1056/NEJMoa1504627. 91. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. …